Serratio peptidase
Reading File
Finding Sources
Searching PubMed
serratiopeptidase clinical efficacy
Finding Sources
Searching PubMed
serratiopeptidase enzyme anti-inflammatory
Searching the Web
serratiopeptidase pharmacology mechanism of action clinical uses
Reading Web Page
https://pmc.ncbi.nlm.nih.gov/articles/PMC9599151
Reading Article
PMID: 36291677
Here is a detailed overview of Serratiopeptidase (also called Serrapeptase):
Serratiopeptidase
Source and Nature
- A zinc-containing metalloprotease (serine protease), molecular weight 45-60 kDa, EC number 3.4.24.40
- Belongs to the Serralysin group
- Originally isolated from Serratia marcescens bacteria found in the intestine of the silkworm Bombyx mori
- Now produced commercially from bacterial fermentation
Mechanism of Action
1. Proteolytic/Anti-inflammatory action
- Breaks down non-living proteins (fibrin, dead tissue, inflammatory exudate)
- Acts on peptide bonds between Arg-Gly, Tyr-Tyr, His-Leu, Gly-Ala, and several others
- Has strong affinity for COX-I and COX-II, thereby reducing production of prostaglandins, thromboxanes, and interleukins
- Reduces bradykinin release (a key pain mediator), explaining its analgesic effect
- Decreases vascular permeability and edema fluid by proteolysis of inflammatory proteins
2. Mucolytic action
- Thins mucus secretions by degrading the mucoprotein network
- Enhances expectoration in respiratory conditions
3. Fibrinolytic action
- Degrades fibrin clots and fibrinous deposits
- Helps dissolve atherosclerotic plaques and venous thrombi (experimental evidence)
4. Anti-biofilm action
- Disrupts bacterial biofilms on tissues and medical devices
- This property is independent of its proteolytic activity (a non-proteolytic mechanism)
- Enhances antibiotic penetration and efficacy (synergistic effect)
5. Enhanced antibiotic penetration
- Promotes penetration of antibiotics and chemotherapeutic agents into infected tissues
Pharmacokinetics
- Given orally as enteric-coated tablets (to protect from gastric acid destruction)
- Must be taken on an empty stomach or 30 minutes before food
- Absorbed intact through the intestinal wall via transcytosis
- Distributed to sites of inflammation via blood and lymphatics
Clinical Indications
| Area | Uses |
|---|---|
| Post-surgical/trauma | Reduction of edema and swelling after surgery, dental extraction, molar surgery |
| ENT | Sinusitis, rhinitis, otitis, bronchitis (mucolytic) |
| Respiratory | Bronchial asthma, COPD, COVID-19 (mucolytic + anti-inflammatory) |
| Musculoskeletal | Carpal tunnel syndrome, osteoarthritis, knee pain, joint infections |
| Dentistry | Post-extraction swelling, trismus, pain management |
| Gynaecology | Fibrocystic breast disease, pelvic inflammatory disease |
| Urology | Epididymitis, cystitis |
| Vascular | Chronic venous insufficiency, venous inflammatory disease |
| Infectious | Post-operative infections (synergy with antibiotics) |
| Neurology (experimental) | Alzheimer's disease - degrades amyloid plaques (animal models only) |
Dose
- Standard oral dose: 5-10 mg (equivalent to 10,000-20,000 IU) given 2-3 times daily, on an empty stomach
- Available as enteric-coated tablets (most common) and in sustained-release formulations
- Combination products: paired with diclofenac, trypsin-bromelain-rutoside, or antibiotics
Comparisons with Other Agents
- In acute inflammation, serratiopeptidase showed superior anti-inflammatory action compared to aspirin, trypsin, and chymotrypsin (carrageenan paw edema model)
- For analgesic effect: weaker than betamethasone and ibuprofen
- For edema/trismus management: comparable to methylprednisolone
- For wound management: combination of trypsin + chymotrypsin showed higher efficacy than serratiopeptidase alone in one study
- Seaprose S showed slightly higher efficacy (85% vs 65%) in venous inflammatory disease
Adverse Effects
Generally well-tolerated. Reported adverse effects:
- Mild gastrointestinal disturbance (nausea, diarrhea) - rare
- Stevens-Johnson syndrome (rare, serious)
- Buccal space abscess (case report)
- Potential adverse effects on joint cartilage at high doses (animal data)
- May be dose-dependent or combination-drug related
Emerging Applications
- Cancer therapy: In vitro cytotoxic activity against colon cancer (Caco-2 cells); nanoparticle co-delivery with curcumin shows enhanced anti-cancer activity against HeLa and MCF-7 cells
- COVID-19: Used as a mucolytic agent in respiratory syndrome management
- Biofilm disruption on medical implants
- Nanoparticle-based drug delivery systems for targeted therapy
Key Advantages Over NSAIDs
- Cheaper and safer alternative to NSAIDs
- Does not cause gastric ulceration or inhibit platelet aggregation
- Suitable for long-term use in chronic inflammatory conditions
Key references:
- Nair & Devi, Biomolecules 2022 - comprehensive multifaceted review (PMID: 36291677)
- Serratiopeptidase: Insights into therapeutic applications, PMC 2020 - detailed mechanisms and clinical data
- Hosseini et al., Arch Microbiol 2024 - biobetter derivatives and metalloprotease applications (PMID: 38502196)
Thiocolcicoside
Finding Sources
Searching PubMed
thiocolchicoside muscle relaxant pharmacology
Searching the Web
thiocolchicoside pharmacology mechanism of action indications dose adverse effects
Reading Article
PMID: 42367456
Reading Web Page
https://www.ema.europa.eu/en/news/european-medicines-agency-…
Here is a detailed overview of Thiocolchicoside:
Thiocolchicoside
Source and Nature
- A semi-synthetic derivative of colchicoside, a natural glucoside obtained from the seeds of Gloriosa superba (also sometimes cited from Colchicum autumnale)
- Structurally related to colchicine but has a distinct pharmacological profile
- Brand names: Muscoril, Myoril, Neoflax
- Classification: Centrally acting skeletal muscle relaxant
Mechanism of Action
The exact mechanism is not fully established, but the following are proposed:
| Receptor | Effect |
|---|---|
| GABA-A receptor | Competitive antagonist (paradoxically promotes muscle relaxation via modulation of inhibitory tone; some sources suggest partial agonism/potentiation) |
| Glycine receptor | Competitive antagonist - inhibits inhibitory glycinergic transmission |
| Nicotinic acetylcholine receptors (nAChR) | Antagonism - believed to be the primary mechanism for muscle relaxation |
Key points:
- Acts on inhibitory neurotransmitter pathways at spinal cord and supraspinal levels
- Achieves muscle relaxation without significant sedation (unlike benzodiazepines), attributed to its lack of strong GABA-A potentiation
- Due to glycine and GABA-A receptor antagonism, it has convulsant potential - must be avoided in seizure-prone individuals
Pharmacokinetics
| Parameter | Detail |
|---|---|
| Absorption | Rapid oral absorption; also available IM |
| Metabolism | Hepatic; key metabolite: 3-demethylthiocolchicine (M2 / SL59.0955) |
| M2 metabolite | Associated with aneuploidy (abnormal chromosome numbers) in dividing cells - the basis of genotoxicity concerns |
| Excretion | Renal |
Indications (Post-EMA Restriction)
Following European Medicines Agency (EMA/CHMP) review, use is now restricted to:
- Add-on treatment for painful muscle contractures associated with spinal column disorders (e.g., acute low back pain, cervical pain, torticollis, lumbar/cervical spondylosis)
- Indicated in adults and adolescents ≥16 years only
Previously used (broader) indications included:
- Spasticity (neurological - MS, cerebral palsy, paraplegia)
- Post-surgical muscle spasm
- Sports injuries
- Osteoarthritis-associated muscle spasm
Dose
| Route | Dose | Maximum Duration |
|---|---|---|
| Oral | 8 mg twice daily (some guidelines: 4-8 mg TID) | ≤7 days |
| Intramuscular (IM) | 4 mg every 12 hours | ≤5 days |
| Topical (gel/cream) | Apply 2-3 times daily | Not restricted by EMA |
Topical preparations are not subject to EMA dose/duration restrictions as systemic absorption is minimal.
Adverse Effects
Common:
- Nausea, diarrhea, GI disturbance
- Dizziness (though less sedating than other muscle relaxants)
- Vasovagal reactions (especially with IM injection)
- Allergic reactions (including immediate hypersensitivity - confirmed by skin testing and basophil activation test)
Serious (recorded in pharmacovigilance databases):
- Seizures / convulsions (due to convulsant activity)
- Liver injury (hepatotoxicity)
- Pancreatitis
- Blood cell disorders (myelosuppression)
- Severe cutaneous reactions (Stevens-Johnson syndrome-like)
- Rhabdomyolysis
- Reproductive toxicity: Altered spermatogenesis, azoospermia (male infertility)
- Teratogenicity: Animal studies show teratogenic potential via M2 metabolite-induced aneuploidy
Contraindications
- Pregnancy and lactation (teratogenic - absolute contraindication)
- Women of childbearing potential not using contraception
- Children under 16 years
- Epilepsy / seizure disorders (convulsant potential)
- Chronic/long-term use - not approved for this
- Hypersensitivity to thiocolchicoside or colchicine derivatives
Safety Concerns - EMA Regulatory Action
The EMA CHMP reviewed evidence showing:
- The metabolite M2 (3-demethylthiocolchicine) causes aneuploidy (abnormal chromosome number, loss of heterozygosity) at levels not much above therapeutic doses
- Aneuploidy is a risk factor for:
- Teratogenicity and embryotoxicity
- Spontaneous abortion
- Impaired male fertility
- Theoretically increased cancer risk (with long-term exposure)
- M2 was NOT associated with mutagenicity or clastogenicity (structural chromosome damage)
Result: EMA restricted indications, dose, and duration; contraindicated in pregnancy and children.
Drug Interactions
- CNS depressants / alcohol: Additive CNS depression risk
- Other convulsant agents: Additive seizure risk
- Colchicine: Structural similarity - caution regarding cumulative toxicity
Comparison with Other Muscle Relaxants
| Feature | Thiocolchicoside | Baclofen | Diazepam | Tizanidine |
|---|---|---|---|---|
| Sedation | Low | Moderate | High | Moderate |
| Convulsant risk | Yes | No | No (anticonvulsant) | No |
| Mechanism | GABA-A/Gly antagonist + nAChR | GABA-B agonist | GABA-A positive modulator | α2 agonist |
| Duration limit | ≤7 days oral | Long-term OK | Short-term preferred | As needed |
| Teratogenic concern | Yes (M2 metabolite) | Category C | Category D | Unknown |
Emerging Research (2026)
- Anticancer potential: In vitro MTT assay studies show cytotoxic activity against cancer cell lines (Devi & Khanwelkar, Cureus 2026, PMID: 42333324)
- Antimicrobial activity: Preclinical studies suggest potential in infectious disease management
- Novel drug delivery: Nanogel-based formulations under investigation to improve bioavailability and reduce systemic toxicity
- Fracture healing: Comparative animal studies evaluating effect on bone healing vs. NSAIDs (Bulum et al., 2026, PMID: 41795074)
- Comprehensive 2026 review: Devi et al., Cureus 2026 covers pharmacological, therapeutic, and toxicological profile in depth
Key Takeaway
Thiocolchicoside is a useful short-term muscle relaxant for spinal pain-related contractures, with the advantage of low sedation. However, its genotoxic metabolite (M2), teratogenicity, convulsant potential, and reproductive toxicity impose strict limits on its use - short treatment courses only, not in pregnancy, not in children, and with caution in seizure-prone patients. The EMA has significantly narrowed its approved indications for systemic use.
This is a shared conversation. Sign in to Orris to start your own chat.